FLNA (FLNA)

Overview

Filana Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative drugs targeting neurodegenerative diseases. With a firm focus on addressing the pressing challenges related to Alzheimer’s disease, Filana's most promising therapeutic candidate is simufilam, a small molecule drug currently undergoing Phase 3 clinical trials. In addition to its therapeutic advancements, the company is also advancing an investigative diagnostic tool, SavaDx, aimed at early detection of Alzheimer’s disease through a minimally invasive blood test. Originally known as Cassava Sciences, Inc., the company rebranded itself to Filana Therapeutics, Inc. in March 2026 and has been actively contributing to the biotechnology sector since its incorporation in 1998, with its headquarters located in Austin, Texas.

Products and Services

• Simufilam:

  Simufilam is a small molecule therapeutic candidate currently in Phase 3 clinical trials designed to treat Alzheimer’s disease. This innovative treatment aims to modify disease progression and improve cognitive function in patients suffering from this debilitating neurodegenerative condition.

• SavaDx:

  SavaDx represents an early-stage investigational diagnostic program focused on detecting Alzheimer’s disease with a simple blood test. This technology aims to identify the presence of the disease early on, offering the potential for timely intervention and improved management of Alzheimer’s.